Table 1. The commercial sources and doses of 18 growth factors and cytokines, designated as the “core factors” as reported by Pennock et al.36.
| Growth factor | Type | Vendor | Catalog number | Effective In vitro dose | Dose used in this study |
|---|---|---|---|---|---|
| VEGF | human | R & D Systems | 293-VE | 2–50 ng/ml | 50 ng/ml |
| PDGF-A | human | R & D Systems | 221-AA | 2–50 ng/ml | 12.5 ng/ml |
| PDGF-AB | human | R & D Systems | 222-AB | 2–50 ng/ml | 50 ng/ml |
| PDGF-B | human | R & D Systems | 220-GMP | 2–50 ng/ml | 12.5 ng/ml |
| PDGF-C | human | R & D Systems | 1687-CC | 2–50 ng/ml | 6.3 ng/ml |
| CTGF | human | Invitrogen | PHG0286 | 2–50 ng/ml | 10 ng/ml |
| EGF | human | R & D Systems | 236-EG | 5–50 ng/ml | 10 ng/ml |
| FGF-2 | human | R & D Systems | 233-FB | 2–50 ng/ml | 20 ng/ml |
| G-CSF | human | PeproTech | AF-300-23 | 5–75 ng/ml | 50 ng/ml |
| HGF | human | R & D Systems | 294-HGN | 2–50 ng/ml | 20 ng/ml |
| IFN-γ | human | PeproTech | AF-300-02 | 0.5–25 ng/ml | 5 ng/ml |
| IGF1 | human | R & D Systems | 291-G1 | 2–50 ng/ml | 10 ng/ml |
| IL-6 | human | R & D Systems | 200-06 | 0.2–10 ng/ml | 10 ng/ml |
| MCP-1 | human | PeproTech | AF-300-04 | 10–100 ng/ml | 100 ng/ml |
| TGF-α | human | PeproTech | AF-100-16A | 5–50 ng/ml | 10 ng/ml |
| TGF-β1 | human | PeproTech | AF-100-21C | 2–20 ng/ml | 10 ng/ml |
| TGF-β2 | human | PeproTech | 100-35 | 2–20 ng/ml | 10 ng/ml |
| TGF-β3 | human | PeproTech | AF-100-36E | 2–20 ng/ml | 10 ng/ml |